Review
Application progress of bone morphogenetic protein 9 in bone regeneration
Zhang Junhe, Ma Jing, Liang Zhuo, Fan Zhenlin, Ren Wenjie
Published 2022-06-08
Cite as Chin J Exp Surg, 2022, 39(6): 1202-1204. DOI: 10.3760/cma.j.cn421213-20211019-01310
Abstract
In bone tissue engineering, as important signaling molecules, growth factors provide new hope for improving bone regeneration. Bone morphogenetic protein-9 (BMP-9), also known as growth differentiation factor 2 (GDF2), is the latest discovery in the BMP family and a bone-forming growth factor with great osteogenic potential, which has been widely used in bone tissue engineering. The Smad cell signaling pathway triggered by BMP is usually inhibited by Noggin, and BMP-9 is resistant to Noggin, which further promotes the differentiation of osteoprogenitor cells into pre-osteoblasts. This review discusses the signal transduction modes of BMP-9 in osteogenesis and the progress of gene therapy in bone tissue engineering, analyzes the application and development of BMP-9 in bone injury repair.
Key words:
Bone morphogenetic protein-9; Bone tissue engineering; Gene therapy
Contributor Information
Zhang Junhe
Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang 453003, China
Ma Jing
Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang 453003, China
Liang Zhuo
Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang 453003, China
Fan Zhenlin
Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang 453003, China
Ren Wenjie
Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang 453003, China